What Is CJC-1295 + Ipamorelin?

Overview

CJC-1295 paired with Ipamorelin is one of the most-studied combination secretagogue models in growth-hormone research. The logic of the pairing is that the two compounds act on different receptors that converge on the same outcome. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) that works through the ghrelin receptor. Studied together, they let researchers examine how two independent inputs to the pituitary interact, rather than isolating a single pathway.

How CJC-1295 + Ipamorelin Works

The two molecules engage separate receptor systems on the anterior pituitary. CJC-1295 binds the GHRH receptor and raises the baseline drive for growth-hormone synthesis and release, extending the signal because the molecule resists rapid enzymatic breakdown. Ipamorelin acts on the ghrelin receptor (GHS-R1a), triggering an additional secretory pulse while sparing cortisol, prolactin and ACTH thanks to its narrow receptor selectivity. Because GHRH and GHRP signals reinforce each other at the pituitary, research models frequently report that the combined response is larger than either compound produces alone — the central reason the GHRH + GHRP pairing is used as a study system for the natural pulsatile growth-hormone axis.

What the Research Explores

Synergistic interaction between GHRH and GHRP signalling and the size of the combined growth-hormone pulse.
Preservation of pulsatile, physiologically patterned secretion compared with steady-state stimulation.
Downstream IGF-1 dynamics and the duration of the secretory response.
Selectivity of the combined model, including the limited spillover onto cortisol and prolactin.
Muscle, connective-tissue and metabolic pathways tied to growth-hormone activity.

Forms & Handling

For combination research the two compounds are usually supplied as separate lyophilized powders — commonly a CJC-1295 vial (with or without the DAC modification) and a 5 mg Ipamorelin vial — though pre-blended vials are also studied. Each is reconstituted with bacteriostatic or sterile water and kept refrigerated once in solution. When the powders are combined in a single vial, the reconstitution math has to account for both peptides so that draw volumes in insulin-syringe units stay accurate. See the dosing protocol linked below for the worked reconstitution figures.

Safety & Research Notes

Both CJC-1295 and Ipamorelin are investigational research compounds. Neither the individual peptides nor the combination has an approved human or veterinary use, and there is no established safety profile for administration. The available literature is limited to laboratory and pre-clinical settings. Everything described here is mechanistic background for research reference only and is not a usage recommendation.

Research-use note. CJC-1295 and Ipamorelin are supplied strictly for in-vitro and laboratory research. They are not approved for human or veterinary use, and nothing on this page constitutes medical advice or dosing instruction.

References

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998). pubmed.ncbi.nlm.nih.gov/9849822
Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. Journal of Clinical Endocrinology & Metabolism (2006). pubmed.ncbi.nlm.nih.gov/16352683
Sinha DK, et al. Beyond the androgen receptor: the role of growth-hormone secretagogues in the male reproductive system. Translational Andrology and Urology (2020). pmc.ncbi.nlm.nih.gov/articles/PMC7108996